


**Supplementary Figure 1. HTII-280<sup>+</sup> cells in distal lung have AT2 phenotype.**

Sup. Fig. 1 is related to Figure 1.


**a** Confocal image of HTII-280 and SFTPC in AT2 cells of peripheral human lung tissue.

Scale bar: 20  $\mu$ m. **b** Overview of the scRNA-seq metrics for the six donor tissues of HTII-280<sup>+</sup> cells and their distribution in UMAP embedding. **c** Overview of the fraction of HTII-280<sup>+</sup> and HTII-280<sup>+</sup>/EpCAM<sup>+</sup> cells in each cluster. **d** Dot plot of cluster marker genes of HTII-280<sup>+</sup> cells.


a



b



c




**Supplementary Figure 2. Alveolar organoids maintain main differentiation markers in the long-term culture.** Sup. Fig. 2 is related to Figure 2 and Figure 3.

**a** CNV analysis of scRNA-seq samples does not indicate presence of contaminating cancer cells.

**b** Validation of the alveolar marker induction by qPCR. n=3, \*p < 0.05; \*\*p < 0.005.


**c** Relative expression (qPCR) of differentiation markers during the long-term cultivation for 3 independent donor lines.




**Supplementary Figure 3. HTII-280<sup>+</sup> derived organoids in CHIR medium show sustained AT2 differentiation.** Sup. Fig. 3 is related to Figure 3 and Figure 4.

**a** Joint embedding of HTII-280<sup>+</sup>-sorted CHIR-treated organoid cells (colored points) together with native lung epithelial cells (gray dots/labels) shows matching expression profiles. **b** CNV analysis of scRNA-seq of airway organoid samples does not indicate presence of contaminating cancer cells. **c** Distribution of cells from individual donors in HTII-280<sup>+</sup> derived organoids. **d** Principal component analysis of average expression profiles for each donor of alveolar organoid lines. **e** Sub-sorted organoids grown in CHIR versus AOM medium over multiple passages show a stable and even increasing alveolar or airway phenotype, respectively, as indicated by high expression of SFTPC and NAPSIN in CHIR medium and TP63 and SCGB1A1 in AOM medium. **f** WB quantification by densitometry of the gsk3 $\beta$  knockdown **g** Validation of FOXM1 upregulation in CHIR-treated HTII-280-derived organoids compared to AOM from two different donors.






**Supplementary Figure 4. Cell composition and differentiation phenotypes in airway organoids (AO) are the same across different donors.** Sup. Fig. 4 is related to Figure 4 and 5. **a** A plot of cell-type proportions in pool airway organoids. **b** Principal component analysis of average expression profiles for each donor. **c** CNV analysis of scRNA-seq of AO samples does not indicate presence of contaminating cancer cells. **d** Selected marker genes of all identified subclusters color-coded for cell-type identities. **e** Dot plot of cluster marker genes for pool airway organoids. **f** Confocal images showing regions of the expanded basal layer (TP63, red, left) as well as differentiated club cells (SCGB1A1, green, middle) and secretory cells (MUC5AC, green, right). Scale bar: 20  $\mu$ m. **g** Quantification of the fraction of ciliated cells with imaging (n=3) calculated as a percentage of ciliated cells per nuclei and by single-cell analysis (n=5).



**Supplementary Figure 5. SHH, NOTCH, and BMP signaling regulate organoid formation and growth.** Sup. Fig. 5 is related to Figure 5 and 6.

**a** Representative phase-contrast images showing the negative effect of inhibition of SHH (Vismodegib) and NOTCH (DAPT) signaling on the formation of organoids. Scale bar: 100  $\mu$ m. **b** Phase-contrast images from two independent donors showing the detrimental effect of noggin removal on the long-term expansion potential of the organoids. Scale bar: 100  $\mu$ m. **c** Combined scRNA-seq analysis of alveolar and airway organoids derived from the same donors shows consistent cell type identification.






**Supplementary Figure 6. Organoids survive IAV infection as infected cells are expelled to the lumen.** Sup. Fig. 6 is related to Figure 7.

**a** Viral replication time course in two different ex vivo infected lung tissues.

**b** Phase-contrast (left) and confocal images (right) at 4 days post-infection (4dpi) show that organoids remain viable, with intact epithelial integrity while debris of infected cells is abundant in the lumen (arrows). Scale bars: 100  $\mu$ m and 50  $\mu$ m.

**c** Overview of likely productively infected, passively infected, and non-infected cells from organoids and ex vivo infected lung tissue in scRNA-seq UMAP plot.


**d** Distribution of main cell type marker genes in lung tissue fragments as analyzed by scRNA-seq.



**Supplementary Figure 7. Raw blots.**

**a** Uncropped blots from Figure 3d. **b** Uncropped blots from Figure 4d.

**c** Uncropped blots from Supplementary Figure 3e. **d** Uncropped blots of Supplementary Figure 3g.



Tube: ht2 a488

Population	#Events	%Parent	%Total
All Events	80,016	####	100.0
P1	70,981	88.7	88.7
P2	70,874	99.8	88.6
P3	69,944	98.7	87.4
P4	67,663	96.7	84.6
P5	530	0.8	0.7
P6	66,836	98.8	83.5
P7	0	0.0	0.0
P8	0	0.0	0.0

**Supplementary Figure 8. Gating strategy for sorting HTII-280<sup>+</sup> cells from lung tissue.**